• LAST PRICE
    0.0243
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 0.0243
  • Day Range
    ---
  • 52 Week Range
    Low 0.0130
    High 0.0855
  • Volume
    ---

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
Table Data Not Available
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBZYR
Burzynski Research Institute Inc
3.2M
-2.7x
---
United StatesBCEL
Atreca Inc
3.2M
0.0x
---
United StatesELOX
Eloxx Pharmaceuticals Inc
3.2M
-0.1x
---
United StatesONCO
Onconetix Inc
3.1M
-0.1x
---
United StatesPHIO
Phio Pharmaceuticals Corp
3.1M
-0.1x
---
United StatesREVB
Revelation Biosciences Inc
3.4M
0.1x
---
As of 2024-04-14

Company Information

Burzynski Research Institute, Inc. is engaged in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids, which are known under the trade name Antineoplastons. Antineoplastons are useful in the treatment of human cancer and is reviewing data from its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons are found in the bodily fluids of humans and food. The Company conducted all the Phase II clinical trials for the treatment of a variety of cancers using the combination of Antineoplastons A10 and AS2-1. Most of the trials involve the use of intravenous formulations of Antineoplastons; however, a few trials use oral formulations. The Company has not generated any operating revenue since its inception. The Company's clinical trials are conducted at the Burzynski Clinic.

Contact Information

Headquarters
12000 Richmond AveHOUSTON, TX, United States 77082
Phone
713-335-5697
Fax
713-935-0649

Executives

Chairman of the Board, President
Stanislaw Burzynski
Vice President - Clinical Trials
Tomasz Janicki
Treasurer, Secretary
Patryk Goscianski
Director
Gregory Burzynski
Director
Monika Szopa - Paszkowiak

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.2M
Revenue (TTM)
$0.00
Shares Outstanding
131.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.53
EPS
$-0.01
Book Value
$0.00
P/E Ratio
-2.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.